Nonmetastatic Castration-resistant Prostate Cancer Articles


  • Apalutamide and Overall Survival in Prostate Cancer.

    The phase 3 SPARTAN study evaluated apalutamide versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) and prostate-specific antigen doubling time of ≤10 mo. At primary analysis, apalutamide improved median metastasis-free survival (MFS) by 2 yr and overall survival (OS) data were immature.

    Published September 15, 2020
  • Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.

    Introduction Enzalutamide is the first characterized second-generation nonsteroidal androgen receptor inhibitor (ARi). Its efficacy has been established in several clinical trials evaluating its role in different settings of prostate cancer.

    Published August 18, 2020
  • Sequencing strategies in the new treatment landscape of prostate cancer.

    Over the last 10 years, a number of new agents approved for the treatment of metastatic castration-resistant prostate cancer have led to a significant improvement in overall survival. The addition of new agents to androgen deprivation therapy has also allowed a paradigmatic change in the treatment of metastatic hormone-sensitive prostate cancer by improving overall survival in comparison with androgen deprivation therapy alone.

    Published August 22, 2019
  • Treatment of non-mestastatic castration resistant prostate cancer in 2020: What is the best?

    Lately the development of 3 novel second-generation androgen receptor antagonists (enzalutamide, apalutamide, and darolutamide) chanced the treatment landscape of nonmetastatic castration-resistant prostate cancer.

    Published January 27, 2020